Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma-Reference-Cited by-同舟云学术

Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma

Published:2020-08-05 Issue:13 Volume:61 Page:3234-3238
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lossos Izidore S.¹²,Reis Isildinha M.³⁴,Rosenblatt Joseph D.¹,Alderuccio Juan Pablo¹

Affiliation:

1. Department of Medicine, Division of Hematology, University of Miami Miller School of Medicine, Miami, FL, USA

2. Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA

3. Department of Public Health Science, University of Miami Miller School of Medicine, Miami, FL, USA

4. Biostatistics and Bioinformatics Core Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1802449

Reference19 articles.

1. Diagnostic bone marrow biopsy in patients with stage I EMZL treated with radiation therapy: needed or not?

2. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy

3. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

4. Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

5. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma;The Oncologist;2024-01-11

2. Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma;Expert Review of Hematology;2023-04-28

3. A Phase II Study of ¹³¹I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma;Clinical Medicine Insights: Oncology;2023-01

4. Immunotherapy for Ocular Tumors;Handbook of Cancer and Immunology;2023

5. Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2022-08